InFuse

Medtronic, building, generic

Senate: Medtronic Shaped Articles Promoting InFuse

A Senate report out Thursday concludes Minneapolis-based Medtronic helped write and edit medical journal articles attributed to outside physicians which downplayed the risks of Infuse, the company’s best-selling bone graft, responsible for $800 million in annual sales.

10/25/2012

Medtronic, building, generic

Medtronic Says Bone Graft Investigation Is Over

Medical device maker Medtronic Inc. said Wednesday that federal prosecutors have closed their investigation of the company’s InFuse bone graft.

05/16/2012

Follow

Get every new post delivered to your Inbox.

Join 2,592 other followers